Fremanezumab
| Evidence Level: L4 | Predicted Indications: 2 |
Table of Contents
Fremanezumab: From Migraine Prevention to Migraine with Brainstem Aura
One-Sentence Summary
Fremanezumab (marketed in the US as AJOVY) is an anti-CGRP monoclonal antibody used to prevent migraine. The TxGNN model predicts it may be effective for migraine with brainstem aura, but so far there are 0 registered clinical trials and 20 publications, and none of them studies this exact subtype directly.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Migraine with brainstem aura |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 2 records (both are the same application, BLA761089) |
| Recommended Decision | Hold (treat as a research question) |
The approved indication text was not included in the supplied regulatory data, so the original indication is not tabulated here.
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the Evidence Pack. Fremanezumab is a humanized monoclonal antibody that targets calcitonin gene-related peptide (CGRP), a vasodilator peptide central to migraine biology. It is already marketed as a migraine preventive, and migraine with brainstem aura is a subtype of migraine. Blocking the CGRP pathway is therefore biologically plausible for this condition.
Preclinical work on cortical spreading depression (CSD), the wave of neuronal depolarization thought to underlie aura, gives only partial support:
- One study found that CSD-induced arterial dilatation and plasma protein extravasation were unaffected by fremanezumab.
- Another found slower CSD propagation and a shorter cortical recovery period, but CSD still occurred.
Clinical data on aura come from case series, case reports and post hoc analyses. No study specifically enrolled or stratified patients with brainstem aura. The evidence is therefore indirect, and the very high TxGNN score has not been confirmed by aura-specific clinical data.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35302681 | 2022 | Post hoc analysis of RCT | Eur J Neurol | Efficacy and quality-of-life outcomes for fremanezumab in the phase 3b FOCUS study, in subgroups with and without aura or similar neurological dysfunction |
| 35268319 | 2022 | Case reports + review | J Clin Med | Asks whether anti-CGRP antibodies prevent migraine aura, noting scarce information on this point |
| 41618146 | 2026 | Individual patient analysis | J Headache Pain | Effectiveness and safety of anti-CGRP antibodies in hemiplegic migraine, a rare aura subtype excluded from RCTs |
| 38332541 | 2024 | Observational case series | CNS Neurosci Ther | Effect of anti-CGRP therapy on migraine aura, where clinical evidence is limited |
| 40264646 | 2025 | Case report + review | Front Neurol | Anti-CGRP antibodies in hemiplegic migraine (a middle-aged woman with chronic migraine) |
| 31127003 | 2019 | Preclinical (CSD model) | J Neurosci | CSD-induced arterial dilatation and plasma protein extravasation were unaffected by fremanezumab |
| 31895266 | 2020 | Preclinical (CSD model) | Pain | Fremanezumab slowed CSD propagation and shortened cortical recovery but did not prevent CSD in rats with a compromised blood-brain barrier |
| 28642283 | 2017 | Preclinical | J Neurosci | Selective inhibition of trigeminovascular neurons by fremanezumab |
| 37638190 | 2023 | Real-world cohort | Front Neurol | 3-month real-world efficacy and tolerability in adults with chronic migraine |
| 35775208 | 2022 | Observational | Cephalalgia | Effects of erenumab, fremanezumab and galcanezumab on prodromal and accompanying symptoms of migraine attacks |
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| BLA761089 | AJOVY | Injection | Teva Pharmaceuticals USA, Inc. |
The Evidence Pack lists this application twice, so only one unique authorization is shown. Approved indication text is not included in the supplied data.
Conclusion and Next Steps
Decision: Hold
Rationale: Fremanezumab is a marketed anti-CGRP antibody, and a link to migraine subtypes is plausible. But there are no trials for brainstem aura, the preclinical CSD data are mixed, and clinical aura evidence is limited to case series, case reports and post hoc analyses. The model score alone is not enough to advance. This is best treated as a research question.
The model’s second prediction, atrophoderma vermiculata (score 99.04%), has no trials or literature and no identifiable mechanistic link to CGRP blockade. It should not be pursued without independent evidence.
To proceed, the following is needed:
- Package insert warnings, contraindications and approved indication text (currently missing, blocking safety screening)
- Mechanism of action data from DrugBank
- Aura-specific evidence, ideally a trial or registry that stratifies patients with brainstem aura
- A check of whether the hemiplegic migraine and aura case data can be extended to brainstem aura
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.